Page 487 - Read Online

Maner et al. J Cancer Metastasis Treat 2020;6:37 I http://dx.doi.org/10.20517/2394-4722.2020.60 Page 39 of 40

to the 7th vs 8th edition of the AJCC cancer staging manual. JAMA Network Open 2018;1:e180083.
188. Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, et al. Identification of patients at risk of metastasis using a prognostic 31-
gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol
2019;80:149-57.e4.
189. Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, et al. Development of a prognostic genetic signature to predict the metastatic
risk associated with cutaneous melanoma. Clin Cancer Res 2015;21:175-83.
190. Gastman BR, Zager JS, Messina JL, Cook RW, Covington KR, et al. Performance of a 31-gene expression profile test in cutaneous
melanomas of the head and neck. Head Neck 2019;41:871-9.
191. Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of
the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol 2020; doi: 10.1016/j.jaad.2020.03.053.
192. Kovarik CL, Chu EY, Adamson AS. Gene expression profile testing for thin melanoma: evidence to support clinical use remains thin.
JAMA Dermatol 2020; doi: 10.1001/jamadermatol.2020.0894.
193. Dalal M, Mitchell S, McCloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and
response to conventional and novel therapies: results of a systematic review. Expert Rev Hematol 2020;13:405-19.
194. Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res 2016;5:1882.
195. Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, et al. Hydrochlorothiazide and cutaneous T cell lymphoma. Cancer
2013;119:825-31.
196. Emge DA, Bassett RL, Duvic M, Huen AO. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in
erythrodermic cutaneous T-cell lymphoma (CTCL) patients. Arch Dermatol Res 2020;312:283-8.
197. Pulitzer M. Cutaneous T-cell lymphoma. Clin Lab Med 2017;37:527-46.
198. Rasheed H, Hegazy RA, Gawdat HI, Mehaney DA, Kamel MM, et al. Serum vitamin D and vitamin D receptor gene polymorphism in
mycosis fungoides patients: a case control study. PLoS One 2016;11:e0158014.
199. Choi J, Goh G, Walradt T, Hong BS, Bunick CG, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015;47:1011-9.
200. Ayhan A, Mao TL, Suryo Rahmanto Y, Zeppernick F, Ogawa H, et al. Increased proliferation in atypical hyperplasia/endometrioid
intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. J Pathol Clin Res
2015;1:186-93.
201. Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nature Reviews Cancer 2015;15:152-65.
202. Gallardo F, Sandoval J, Díaz-Lagares A, Garcia R, D’Altri T, et al. Notch1 pathway activation results from the epigenetic abrogation of
notch-related micrornas in mycosis fungoides. J Invest Dermatol 2015;135:3144-52.
203. Dotto GP. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer 2009;9:587-95.
204. Espinosa L, Cathelin S, D’Altri T, Trimarchi T, Statnikov A, et al. The Notch/Hes1 pathway sustains NF-κB Activation through CYLD
repression in T cell leukemia. Cancer Cell 2010;18:268-81.
205. Manfè V, Biskup E, Rosbjerg A, Kamstrup M, Skov AG, et al. miR-122 regulates p53/Akt signalling and the chemotherapy-induced
apoptosis in cutaneous T-cell lymphoma. PLoS One 2012;7:e29541.
206. Walia R, Yeung CCS. An update on molecular biology of cutaneous T cell lymphoma. Front Oncol 2020;9:1558.
207. Wahnschaffe L, Braun T, Timonen S, Giri AK, Schrader A, et al. JAK/STAT-activating genomic alterations are a hallmark of T-PLL.
Cancers 2019;11:1833.
208. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-3.
209. Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies
recurrent alterations in TNFR2. Nat Genet 2015;47:1056-60.
210. Espinosa L, Cathelin S, D’Altri T, Trimarchi T, Statnikov A, et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD
repression in T cell leukemia. Cancer Cell 2010;18:268-81.
211. Vaqué JP, Gómez-López G, Monsálvez V, Varela I, Martínez N, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood
2014;123:2034-43.
212. Pomerantz JL, Denny EM, Baltimore D. CARD11 mediates factor-specific activation of NF-κB by the T cell receptor complex. EMBO J
2002;21:5184-94.
213. Braun FCM, Grabarczyk P, Möbs M, Braun FK, Eberle J, et al. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary
syndrome. Leukemia 2011;25:1494-501.
214. McGirt LY, Degesys CA, Johnson VE, Zic JA, Zwerner JP, et al. TOX expression and role in CTCL. J Eur Acad Dermatol Venereol
2016;30:1497-502.
215. Kremer KN, Dinkel BA, Sterner RM, Osborne DG, Jevremovic D, et al. TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via
a PREX1-Rac1 pathway: implications for CTCL. Blood 2017;130:982-94.
216. Tanase C, Popescu I, Enciu AM, Gheorghisan-Galateanu A, Codrici E, et al. Angiogenesis in cutaneous T-cell lymphoma - proteomic
approaches (Review). Oncol Lett 2019;17:4060-7.
217. Liszewski W, Naym DG, Biskup E, Gniadecki R. Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is
augmented by type I interferons via the JAK1-STAT1 pathway. Photodermatol Photoimmunol Photomed 2017;33:164-71.
218. Shea L, Mehta-Shah N. Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma. Curr
Hematol Malig Rep 2020;15:9-19.
219. Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary
syndrome): Part II. Prognosis, management, and future directions. J Am Acad Dermatol 2014;70:223.e1-17.